aileron therapeutics completes enrollment in cohort 2 of the ongoing phase 1b clinical trial evaluating lti-03 in idiopathic pulmonary fibrosis (ipf)
Cohort 2 will evaluate high-dose LTI-03 (5 mg BID) Previously announced Cohort 1 data demonstrated positive trends in seven of...